TY - JOUR
T1 - Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months
T2 - A call for new metrics for left ventricular assist device patients
AU - On behalf of the MOMENTUM 3 Investigators
AU - Cowger, Jennifer A.
AU - Naka, Yoshifumi
AU - Aaronson, Keith D.
AU - Horstmanshof, Douglas
AU - Gulati, Sanjeev
AU - Rinde-Hoffman, Debbie
AU - Pinney, Sean
AU - Adatya, Sirtaz
AU - Farrar, David J.
AU - Jorde, Ulrich P.
N1 - Publisher Copyright:
© 2018 International Society for the Heart and Lung Transplantation
PY - 2018/1
Y1 - 2018/1
N2 - Background The Multicenter Study of MAGLEV Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial demonstrated improved 6-month event-free survival, but a detailed analysis of health-related quality of life (HR-QOL) and functional capacity (FC) was not presented. Further, the effect of early serious adverse events (SAEs) on these metrics and on the general ability to live well while supported with a left ventricular assist system (LVAS) warrants evaluation. Methods FC (New York Heart Association [NYHA] and 6-minute walk test [6MWT]) and HR-QOL (European Quality of Life [EQ-5D-5L] and the Kansas City Cardiomyopathy [KCCQ]) assessments were obtained at baseline and 6 months after HeartMate 3 (HM3, n = 151; Abbott, Abbott Park, IL) or HeartMate II (HMII, n = 138; Abbott) implant as part of the MOMENTUM 3 clinical trial. Metrics were compared between devices and in those with and without events. The proportion of patients “living well on an LVAS” at 6 months, defined as alive with satisfactory FC (NYHA I/II or 6MWT > 300 meters) and HR-QOL (overall KCCQ > 50), was evaluated. Results Although the median (25th–75th percentile) patient KCCQ (change for HM3: +28 [10–46]; HMII: +29 [9–48]) and EQ-5D-5L (change for HM3: –1 [–5 to 0]; HMII: –2 [–6 to 0]) scores improved from baseline to 6 months (p < 0.05), there were no differences between devices (p > 0.05). Likewise, there was an equivalent improvement in 6MWT distance at 6 months in HM3 (+94 [1–274] meters] and HMII (+188[43–340 meters]) from baseline. In patients with SAEs (n = 188), 6MWTs increased from baseline (p < 0.001), but gains for both devices were less than those without SAE (HM3: +74 [–9 to 183] meters with SAE vs +140 [35–329] meters without SAE; HMII: +177 [47–356] meters with SAE vs +192 [23–337] meters without SAE, both p < 0.003). SAEs did not affect the 6-month HR-QOL scores. The “living well” end point was achieved in 145 HM3 (63%) and 120 HMII (68%) patients (p = 0.44). Conclusions Gains in HR-QOL and FC were similar early after HM3 and HMII implant. 6MWT improvements were attenuated in patients experiencing SAEs, but HR-QOL metrics did not change. The development of left ventricular assist device–specific HR-QOL tools is needed to better characterize the effect of SAEs on a patient's well-being. Clinical Trial No MOMENTUM 3 clinical trial #NCT02224755.
AB - Background The Multicenter Study of MAGLEV Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial demonstrated improved 6-month event-free survival, but a detailed analysis of health-related quality of life (HR-QOL) and functional capacity (FC) was not presented. Further, the effect of early serious adverse events (SAEs) on these metrics and on the general ability to live well while supported with a left ventricular assist system (LVAS) warrants evaluation. Methods FC (New York Heart Association [NYHA] and 6-minute walk test [6MWT]) and HR-QOL (European Quality of Life [EQ-5D-5L] and the Kansas City Cardiomyopathy [KCCQ]) assessments were obtained at baseline and 6 months after HeartMate 3 (HM3, n = 151; Abbott, Abbott Park, IL) or HeartMate II (HMII, n = 138; Abbott) implant as part of the MOMENTUM 3 clinical trial. Metrics were compared between devices and in those with and without events. The proportion of patients “living well on an LVAS” at 6 months, defined as alive with satisfactory FC (NYHA I/II or 6MWT > 300 meters) and HR-QOL (overall KCCQ > 50), was evaluated. Results Although the median (25th–75th percentile) patient KCCQ (change for HM3: +28 [10–46]; HMII: +29 [9–48]) and EQ-5D-5L (change for HM3: –1 [–5 to 0]; HMII: –2 [–6 to 0]) scores improved from baseline to 6 months (p < 0.05), there were no differences between devices (p > 0.05). Likewise, there was an equivalent improvement in 6MWT distance at 6 months in HM3 (+94 [1–274] meters] and HMII (+188[43–340 meters]) from baseline. In patients with SAEs (n = 188), 6MWTs increased from baseline (p < 0.001), but gains for both devices were less than those without SAE (HM3: +74 [–9 to 183] meters with SAE vs +140 [35–329] meters without SAE; HMII: +177 [47–356] meters with SAE vs +192 [23–337] meters without SAE, both p < 0.003). SAEs did not affect the 6-month HR-QOL scores. The “living well” end point was achieved in 145 HM3 (63%) and 120 HMII (68%) patients (p = 0.44). Conclusions Gains in HR-QOL and FC were similar early after HM3 and HMII implant. 6MWT improvements were attenuated in patients experiencing SAEs, but HR-QOL metrics did not change. The development of left ventricular assist device–specific HR-QOL tools is needed to better characterize the effect of SAEs on a patient's well-being. Clinical Trial No MOMENTUM 3 clinical trial #NCT02224755.
KW - MOMENTUM 3
KW - functional capacity
KW - health-related quality of life
KW - left ventricular assist system
KW - living well on LVAS
KW - serious adverse evens
UR - http://www.scopus.com/inward/record.url?scp=85033799917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033799917&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2017.10.019
DO - 10.1016/j.healun.2017.10.019
M3 - Article
C2 - 29153637
AN - SCOPUS:85033799917
SN - 1053-2498
VL - 37
SP - 15
EP - 24
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 1
ER -